Work

Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.4572

Authors: Nizar M. Tannir, Camillo Porta, Viktor Gruenwald, Toni K. Choueiri, Qasim Ahmad, Marlene Carrasco Alfonso, Luca Dezzani, Jackie Han, Cora N. Sternberg

Institutions: The University of Texas MD Anderson Cancer Center, Medizinische Hochschule Hannover, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Azienda Ospedaliera San Camillo-Forlanini

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891825846

Cites:

Cited by: 4

Related to: 10